Trinity Biotech PLC (TRIB) Earning Somewhat Favorable News Coverage, Report Finds
Media headlines about Trinity Biotech PLC (NASDAQ:TRIB) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Trinity Biotech PLC earned a media sentiment score of 0.00 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.3168149935076 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Several research firms have issued reports on TRIB. Zacks Investment Research lowered Trinity Biotech PLC from a “buy” rating to a “hold” rating in a research note on Wednesday. ValuEngine lowered Trinity Biotech PLC from a “hold” rating to a “sell” rating in a research note on Friday, June 2nd.
Shares of Trinity Biotech PLC (NASDAQ:TRIB) traded up 2.23% during mid-day trading on Friday, hitting $5.50. The stock had a trading volume of 25,029 shares. Trinity Biotech PLC has a 1-year low of $5.11 and a 1-year high of $13.68. The company’s market capitalization is $120.16 million. The stock’s 50-day moving average price is $5.62 and its 200 day moving average price is $5.71.
Trinity Biotech PLC (NASDAQ:TRIB) last released its earnings results on Thursday, July 20th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by $0.03. Trinity Biotech PLC had a negative net margin of 100.45% and a positive return on equity of 5.54%. The company had revenue of $25.45 million for the quarter, compared to the consensus estimate of $24.83 million. On average, analysts predict that Trinity Biotech PLC will post $0.27 EPS for the current fiscal year.
WARNING: This piece was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/01/trinity-biotech-plc-trib-earning-somewhat-favorable-news-coverage-report-finds.html.
Trinity Biotech PLC Company Profile
Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine.
Receive News & Stock Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related stocks with our FREE daily email newsletter.